Compare · ATRA vs MRKR

ATRA vs MRKR

Side-by-side comparison of Atara Biotherapeutics Inc. (ATRA) and Marker Therapeutics Inc. (MRKR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ATRA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while MRKR focuses on Biotechnology: Pharmaceutical Preparations.
  • ATRA is the larger of the two at $64.5M, about 3.5x MRKR ($18.2M).
  • ATRA has been more active in the news (5 items in the past 4 weeks vs 3 for MRKR).
  • ATRA has more recent analyst coverage (10 ratings vs 2 for MRKR).
MetricATRAMRKR
Company
Atara Biotherapeutics Inc.
Marker Therapeutics Inc.
Price
-
-
Market cap
$64.5M
$18.2M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2014
News (4w)
5
3
Recent ratings
10
2
ATRA

Atara Biotherapeutics Inc.

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

MRKR

Marker Therapeutics Inc.

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Latest ATRA

Latest MRKR